Study points to value of PET amyloid imaging in clinical setting

12/4/2012 | Medscape (free registration)

PET imaging with 18F-florbetapir was able to detect amyloid deposits in 113 of 229 patients assessed for progressive cognitive decline or impairment of uncertain etiology, according to a study published in Alzheimer Disease & Associated Disorders. Data from the scans prompted physicians to modify diagnosis in 54.6% of patients. The PET scans also led to at least one change in the prescan therapy plan in nearly 87% of patients and to an increase of about 20% in physicians' diagnostic confidence ratings.

View Full Article in:

Medscape (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC